Welcome to our dedicated page for Earth Science Tech SEC filings (Ticker: ETST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Earth Science Tech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Earth Science Tech's regulatory disclosures and financial reporting.
Earth Science Tech, Inc. reports that on August 11, 2026 it entered into an agreement to acquire Meduvo LLC, a compounding pharmacy based in La Verne, California. The consideration was not disclosed, with the company stating the amount was immaterial.
Meduvo currently operates from a 2,000-square-foot facility and compounds and dispenses non-sterile medications. The acquisition creates a West Coast operational hub and expands Earth Science Tech’s compounding pharmacy network to 34 U.S. jurisdictions, with regulatory approvals for remaining states actively pending as the company seeks nationwide coverage.
The seller is Mario G. Tabraue, the company’s Chief Operations Officer and board member, making this a related party transaction. Independent directors reviewed and approved the deal, stating the terms were fair, reasonable, and comparable to those available from unaffiliated third parties. Management plans facility upgrades to meet sterility requirements and targets full regulatory certification for sterile compounding by the end of 2028.
Earth Science Tech, Inc. reported fiscal first quarter 2027 results for the period ended June 30, 2026, showing modest revenue growth and much stronger profitability. Revenue was $9.0 million compared to $8.8 million, with gross profit of $6.3 million compared to $6.1 million.
Net income rose 57% to $715,697 from $456,714, and diluted EPS more than tripled to $0.003 from $0.001. Net cash provided by operating activities increased 108.4% to $707,131 from $339,376, and total assets reached $10.4 million on June 30, 2026, up from $7.8 million a year earlier. All key operating subsidiaries were profitable. The company repurchased and retired over 3.7 million shares of common stock during the quarter, compared to 505,000 in the prior-year period, without adding debt. An Annual Meeting on August 31, 2026 will address proposals including cancellation of Series B Preferred Stock and discussion of a potential exchange uplisting.
Earth Science Tech, Inc., a diversified health and wellness holding company, reported revenue of $9,025,779 for the three months ended June 30, 2026, a 3% increase from $8,760,190 a year earlier. Gross profit rose to $6,275,269, with gross margin remaining stable at approximately 70% in both periods.
Total operating expenses decreased 3% to $5,697,468, driven mainly by a 15% reduction in salaries expense after voluntary compensation adjustments by the CEO and COO, while advertising and marketing and professional fees increased to support growth. Net income rose 57% to $715,697 and earnings per share increased to $0.003 from $0.001. Operating cash flow improved to $707,131. As of June 30, 2026, total assets were $10,374,013 and total liabilities $3,009,743, with no long-term debt and equity of $7,364,270. The company repurchased and retired 3,733,726 common shares for $392,191, leaving 287,590,881 common shares outstanding and maintaining 1,000,000 super-voting Series B preferred shares held by the CEO, who has voting control.
Earth Science Tech, Inc. calls a virtual 2026 annual stockholder meeting on August 31, 2026 to elect seven directors, ratify Semple, Marchal & Cooper, LLP as auditor for the year ending March 31, 2027, and hold several non-binding advisory votes.
These advisory items include authorizing negotiations to purchase and retire CEO-held Series B Preferred Stock with super-voting rights for cash, recommending a reverse stock split solely to help meet uplisting bid-price requirements, and approving executive compensation and the frequency of future say-on-pay votes.
Stockholders of record on July 2, 2026, when 287,590,881 shares of common stock were outstanding, may vote one vote per share; a quorum requires 143,795,441 shares. CEO Giorgio R. Saumat beneficially owns 123,737,006 common shares plus all 1,000,000 Series B Preferred, representing 43.03% of voting capital stock. Executive pay is entirely cash-based and non-dilutive; in fiscal 2026 the CEO received total compensation of $3,233,735 and the COO $2,505,415, subject to an advisory say-on-pay vote.
Earth Science Tech, Inc. is asking stockholders to vote at the 2026 virtual annual meeting on six items: electing seven directors for one-year terms, ratifying Semple, Marchal & Cooper, LLP as auditor for the year ending March 31, 2027, and several advisory proposals.
The key advisory items are: authorizing the Board to negotiate an all-cash purchase and retirement of the CEO-held Series B Preferred Stock, which has super-voting powers; recommending a potential reverse stock split in a range of 1-for-2 to 1-for-30 if needed to meet uplisting bid-price requirements; approving a strictly cash-based executive pay program with a $1,758,000 CEO base salary and large performance bonuses; and setting the “say‑on‑pay” frequency at every three years. There were 287,590,881 common shares outstanding as of July 2, 2026, and the Board recommends voting FOR all proposals and a triennial say‑on‑pay vote.
Earth Science Tech, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on August 24, 2026. The company asks holders of 287,590,881 shares outstanding as of the record date to vote on seven proposals: election of seven directors; ratification of Semple, Marchal & Cooper, LLP as independent auditor; a non-binding advisory vote to allow the Board to propose purchasing and retiring the Series B Preferred Stock; a non-binding advisory vote authorizing the Board to effect a reverse stock split if needed to pursue uplisting; a non-binding say-on-pay advisory vote and a separate advisory vote on the frequency of future say-on-pay votes.
The proxy discloses governance steps including an independent Special Committee to negotiate any Series B purchase (the CEO, who holds Series B shares, will abstain on that vote), recent investor-relations engagement, and the Board’s recommendation to vote "FOR" each recommended proposal.
Earth Science Tech, Inc. Schedule 13G filing: Giorgio R. Saumat reports beneficial ownership of 123,737,006 shares of Common Stock, representing 42.94% of the class as of 06/22/2026. The filing states Mr. Saumat has sole voting and sole dispositive power over these shares.
Earth Science Tech, Inc. reported full-year results for the fiscal year ended March 31, 2026, showing higher revenue and earnings while reducing debt. Revenue increased to $35,695,614 from $33,117,624, and net income rose to $3,600,937 from $3,253,635, with earnings per share improving to $0.012.
The company ended the year with total assets of $8,969,337 and total liabilities of $1,928,573, resulting in total equity of $7,040,764. Management highlighted positive operating cash flow, a stronger balance sheet without adding new debt, and share repurchases and retirements of more than 7.1 million common shares in fiscal 2026, plus over 3.1 million additional shares bought in fiscal Q1 2027.
Earth Science Tech, Inc. reports another profitable year, growing revenue to $35.7 million and net income to $3.6 million for the year ended March 31, 2026. The health and wellness holding company, built around compounding pharmacies, telemedicine and a small consumer brand, generated a 71% gross margin.
Operating expenses rose 6% as marketing more than tripled to support growth, while salaries and general and administrative costs declined. Cash from operations was $1.9 million, funding $1.9 million of investment and $0.7 million of financing outflows, including stock repurchases.
Total liabilities fell to $1.9 million and long‑term debt was eliminated, helping boost total equity to $7.0 million. The company repurchased and cancelled shares, and states it has not issued equity since early 2023, emphasizing non‑dilutive financing and an authorized $10 million share repurchase program.
Earth Science Tech, Inc. provided a shareholder update highlighting major milestones for the fiscal year ended March 31, 2026. The company reports repurchasing over 6.9 million shares of common stock since fiscal Q1 2026 and states it has been cash flow positive across its operating platform while pursuing debt-free growth.
The Health/Wellness segment is described as the core operating engine expected to generate most revenue, with Peaks Curative surpassing $2 million in revenue in the first week of fiscal Q4 2026. Management also notes three additional properties under development awaiting final permits and says 3,150,392 shares of common stock have been retired quarter-to-date, positioning the company, in its view, in real financial strength entering the new fiscal year.